Table 1 Number of studies identified through the systematic review.
From: Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis
Group I pharmaceuticals | Outcome cancer | Identification | Screening | Included | ||
|---|---|---|---|---|---|---|
Records identified from databases (n) | Records screened (n) | Reports sought for retrieval | Reports assessed for eligibility (n) | Studies included in final review (n) | ||
Cyclosporine | Skin | 2522 | 2522 | 39 | 39 | 13 |
Hematologic | 8444 | 8444 | 106 | 106 | 6 | |
Cyclophosphamide | Bladder | 1782 | 1782 | 20 | 20 | 3 |
Hematologic | 50,301 | 50,301 | 81 | 81 | 7 | |
Azathioprine | Skin | 1854 | 1854 | 31 | 31 | 13 |
Hematologic | 4027 | 4027 | 50 | 50 | 12 | |
Busulfan | Hematologic | 5131 | 5131 | 25 | 25 | 2 |
Methoxsalen + UV | Skin | 642 | 642 | 25 | 25 | 1 |
Melphalan | Hematologic | 8358 | 8358 | 30 | 30 | 3 |
Chlorambucil | Hematologic | 4965 | 4965 | 13 | 13 | 2 |
Thiotepa | Hematologic | 1883 | 1883 | 4 | 4 | 1 |
Treosulfan | Hematologic | 59 | 59 | 2 | 2 | 0 |
MOPP | Hematologic | 445 | 445 | 2 | 2 | 0 |
Lung | 677 | 677 | 16 | 16 | 1 | |
BEP | Hematologic | 63 | 63 | 9 | 9 | 0 |
Etoposide | Hematologic | 4746 | 4746 | 13 | 13 | 1 |
